This document contains a detailed financial analysis of Valeant Pharmaceuticals (VRX) for the fiscal year 2016 and projections for 2017 and 2018. It includes revenue, EBITDA, interest, taxes, cash flow, debt structure, and market valuation metrics.
doj/DataSet10/EFTA01385412.pdf
{"title":"Valeant Pharmaceuticals (VRX) Financial Data","document_date":"2018-01-03","document_type":"tabular","key_organizations":["Valeant Pharmaceuticals","Deutsche Bank Securities Inc."],"reference_numbers":["DB-SDNY-0086696","SDNY_GM_00232880","EFTA01385412"]}